Form 4: NovoCure CEO Ashley Cordova Reports Share Acquisition Through Employee Share Purchase Plan
SEC Form 4
CEO Ashley Cordova reports acquiring 373 ordinary shares of NovoCure Ltd. through the company's Employee Share Purchase Plan (ESPP) at a price of $14.748 per share.
Summary
- Ashley Cordova, CEO of NovoCure Ltd, reported the acquisition of 373 ordinary shares on December 31, 2024.
- The shares were acquired through the NovoCure Limited Employee Share Purchase Plan (ESPP).
- The purchase price was $14.748 per share.
- The shares were purchased based on 85% of the closing price of the issuer's ordinary shares on July 1, 2024.
- Following the transaction, Cordova directly owns 219,552 ordinary shares.
Sentiment
Score: 7
Explanation: Routine transaction indicating confidence. No negative indicators.
Positives
- The CEO's participation in the ESPP demonstrates confidence in the company's future.
Industry Context
Executive participation in employee share purchase plans is a common practice, aligning management's interests with those of shareholders.
Stakeholder Impact
- The transaction signals to shareholders that the CEO is invested in the company's success.
Key Dates
| Date | Description |
|---|---|
| July 1, 2024 | Date used to determine the purchase price of shares under the ESPP (85% of closing price). |
| July 26, 2022 | Date of the Limited Power of Attorney document. |
| December 31, 2024 | Date of the share acquisition by Ashley Cordova through the ESPP. |
| January 3, 2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.